Moderna and Australia announced collaboration to bring mRNA manufacturing to Australia
On Dec. 13, 2021, Moderna announced an agreement with the Australian Government to build a state-of-the-art messenger RNA…
Moderna launched AI Academy in partnership with Carnegie Mellon University
On Dec. 9, 2021, Moderna announced the launch of its Artificial Intelligence Academy, an innovative initiative that will…
Pfizer and BioNTech received positive CHMP opinion for COMIRNATYﾮ in children 5 to under 12 years of age in the EU
On Nov. 25, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
CureVac published in Nature preclinical data of second-generation COVID-19 candidate
On Nov. 18, 2021, CureVac announced the online publication of the extended preclinical study of the second-generation vaccine…
Health Canada authorized booster dose of Moderna’s COVID-19 vaccine in individuals 18 years of age and older
On Nov. 15, 2021, Moderna confirmed that Health Canada had authorized the use of a booster dose of…
Zipline, Pfizer and BioNTech paved way for automated, on-demand delivery of first mRNA COVID-19 vaccines in Ghana
On Nov. 11, 2021, Zipline, Pfizer and BioNTech announced that Zipline had successfully completed the first long-range drone…
Moderna filed to expand the conditional Marketing Authorization for COVID-19 vaccine in the EU to include children ages 6-11 years
On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…
Moderna updated timing of U.S. Emergency Use Authorization of its COVID-19 vaccine for adolescents
On Oct. 31, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had notified the Company…
BioNTech planned to initiate construction of an mRNA vaccine manufacturing facility in Africa in mid-2022
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
COVID-19 infection presents greater risk of causing very rare neurological events than vaccines
On Oct. 25, 2021, scientists at Oxford University reported that Infection with COVID-19 carried a much higher risk…
Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age
On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…
COVID-19 booster increased antibody responses, was protective in rhesus macaques
On Oct. 21, 2021, the National Institutes of Health announced that a booster dose of the mRNA-1273 COVID-19…
Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.
On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
Moderna announced FDA Advisory Committee unanimously voted in support of EUA for booster dose of COVID-19 vaccine
On Oct. 14, 2021, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
CureVac shifted focus of COVID-19 vaccine development to second-generation mRNA technology
On Oct. 12, 2021, CureVac announced the strategic decision to focus its COVID-19 vaccine development towards the development…
Moderna announced state-of-the-art mRNA facility in Africa to manufacture up to 500 million doses per year
On Oct. 7, 2021, Moderna announced it was building a state-of-the-art mRNA facility in Africa with the goal…
2022 Breakthrough Prize in Life Sciences awarded to Penn Medicine mRNA pioneers Drew Weissman and Katalin Karik
On Sept. 29, 2021, the University of Pennsylvania announced that the Breakthrough Prize in Life Sciences was awarded…
Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…
Pfizer announced Study of mRNA-based next generation flu vaccine program
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine
On Sept. 24, 2021, Moderna announced a supply agreement with the government of Peru for 20 million doses…
Biotechnology | COVID-19 | Genomics | HIV | Vaccine
Winners of 2022 Breakthrough Prizes In Life Sciences announced
On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…
Moderna announces Health Canada approves its COVID-19 vaccine
On Sept. 16, 2021, Moderna announced Health Canada had approved the New Drug Submission (NDS-CV) for SPIKEVAX (elasomeran…
Emergent BioSolutions announced manufacturing agreement with Providence Therapeutics for mRNA COVID-19 vaccine candidate
On Sept. 14, 2021, Emergent BioSolutions announced a five-year contract development and manufacturing (CDMO) services agreement spanning Emergentﾒs…
Twist Bioscience committed to deliver synthetic RNA controls to fight Delta plus variants of COVID-19
On Sept. 14, 2021, Twist Bioscience announced that it had started shipping its synthetic RNA reference controls for…
Resilience to manufacture mRNA for Moderna’s COVID-19 vaccine
On Sept. 8, 2021, National Resilience announced an agreement to manufacture mRNA for the Moderna COVID-19 vaccine. Under…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY
On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…
Moderna announced submission of data to EMA for its COVID-19 vaccine booster
On Sept. 3, 2021, Moderna announced that it had submitted for a conditional marketing approval (CMA) with the…
Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine booster
On Sept. 1, 2021, Moderna announced it had initiated its submission to the U.S. Food and Drug Administration…